用于难治性和罕见病的中医药:研究进展与未来策略

Traditional Chinese medicine for intractable and rare diseases: Research progress and future strategies.

作者信息

Liu Yuanzheng, Ren Yanming, Song Peipei

机构信息

Department of Traditional Chinese Medicine, Medical College, Qinghai University, Xining, China.

Center for Clinical Sciences, Japan Institute for Health Security, Tokyo, Japan.

出版信息

Intractable Rare Dis Res. 2025 May 31;14(2):109-121. doi: 10.5582/irdr.2025.01028.

Abstract

Rare diseases have become a global public health challenge due to their low prevalence, difficult diagnosis, and limited treatment options. Intractable diseases are more common but often involve complex mechanisms, treatment with limited efficacy, and high medical costs, placing a heavy burden on patients and healthcare systems. In recent years, traditional Chinese medicine (TCM) has demonstrated unique advantages in the treatment of intractable and rare diseases and has gradually become an important complementary treatment. The current work is a systematic review of the progress of clinical and experimental research on TCM in typical rare diseases such as amyotrophic lateral sclerosis (ALS), systemic lupus erythematosus (SLE), mitochondrial encephalomyopathy, aplastic anemia (AA), and Wilson's disease (WD). It focuses on the multi-target therapeutic mechanisms of key Chinese herbal compound formulas, including immune regulation, antioxidative stress, and neuroprotection. The core TCM theories of "syndrome differentiation", "different treatments for the same disease" and the "same treatment for different diseases" are also discussed in the context of personalized medicine. In recent years, China has continuously promoted the development of TCM through a series of national plans and supportive policies, such as the 14th Five-Year Plan for TCM development, funding for key special projects, expedited approval pathways, and expanded coverage by medical insurance. These efforts have provided strong support for the clinical translation of TCM and technological innovation in the field of intractable and rare diseases. Notwithstanding the encouraging advances, the field of Chinese medicine continues to grapple with numerous challenges. In the future, the enhancement of mechanistic studies and quality multicenter clinical trials needs to be promoted while further enhancing policy support and international collaboration to substantiate the scientific basis and clinical value of TCM in the prevention and treatment of intractable and rare diseases.

摘要

罕见病因其患病率低、诊断困难和治疗选择有限,已成为全球公共卫生挑战。难治性疾病更为常见,但往往涉及复杂机制、疗效有限的治疗方法以及高昂的医疗成本,给患者和医疗系统带来沉重负担。近年来,中医在治疗难治性和罕见病方面展现出独特优势,并逐渐成为重要的辅助治疗方法。当前工作是对中医在肌萎缩侧索硬化症(ALS)、系统性红斑狼疮(SLE)、线粒体脑肌病、再生障碍性贫血(AA)和威尔逊病(WD)等典型罕见病临床及实验研究进展的系统综述。它聚焦于关键中药复方的多靶点治疗机制,包括免疫调节、抗氧化应激和神经保护。“辨证论治”“同病异治”和“异病同治”等中医核心理论也在个性化医疗背景下进行了讨论。近年来,中国通过一系列国家规划和支持政策不断推动中医发展,如中医发展“十四五”规划、关键专项资助、加快审批途径以及扩大医保覆盖范围。这些努力为中医临床转化以及难治性和罕见病领域的技术创新提供了有力支持。尽管取得了令人鼓舞的进展,但中医领域仍面临诸多挑战。未来,需要推动加强机制研究和高质量多中心临床试验,同时进一步加强政策支持和国际合作,以证实中医在预防和治疗难治性和罕见病方面的科学依据和临床价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索